Compare GSK plc (GSK) vs Wahed FTSE USA Shariah ETF (HLAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Wahed FTSE USA Shariah ETF — how do they compare? GSK plc trades at $50.56 (market cap $102.60B), while Wahed FTSE USA Shariah ETF trades at $72.96. The key difference: GSK plc pays a 3.57% dividend while Wahed FTSE USA Shariah ETF pays none, and Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| GSK | HLAL | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | Sector/Thematic |
52-Week High | $61.18 | $73.60 |
52-Week Low | $38.22 | $55.52 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
HLAL trades at $72.93, showing minimal daily movement with a slight 0.06% decline. Technical indicators present a mixed picture with bullish moving averages but neutral oscillators, while the stock lacks comprehensive fundamental data for traditional valuation metrics. The upcoming dividend of $0.02 per share scheduled for June 2026 provides a modest income component.
The stock's outlook remains uncertain due to limited financial disclosures. Investment opportunity hinges on future earnings visibility and market positioning, while primary risks include information gaps and market volatility. Further fundamental analysis requires updated SEC filings and earnings reports to assess true valuation potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →
